HCA
CPRX

Harbor Capital Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Harbor Capital Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15K Buy
616
+359
+140% +$8.55K ﹤0.01% 886
2025
Q4 		$6K Sell
257
-4
-2% -$89 ﹤0.01% 1085
2025
Q3 		$5K Sell
261
-7
-3% -$144 ﹤0.01% 1150
2025
Q2 		$6K Buy
268
+37
+16% +$873 ﹤0.01% 1102
2025
Q1 		$6K Buy
+231
New +$5.2K ﹤0.01% 1113

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Harbor Capital Advisors's CPRX Position: Q1 2026 in Review

Harbor Capital Advisors increased its Catalyst Pharmaceutical (CPRX) stake by 140% in Q1 2026, buying an estimated $8.55K and bringing the position to 616 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #886.

Harbor Capital Advisors first reported a position in CPRX in Q1 2025 and has held it in 5 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Harbor Capital Advisors held 616 shares of Catalyst Pharmaceutical worth $15K as of Q1 2026.
  • Harbor Capital Advisors bought 359 Catalyst Pharmaceutical shares in Q1 2026, an estimated $8.55K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Harbor Capital Advisors's portfolio in Q1 2026, its #886 holding.
  • Harbor Capital Advisors first reported a position in Catalyst Pharmaceutical in Q1 2025 and has held it in 5 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Harbor Capital Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.